Haowen Xu

Haowen Xu

Auto-generated profile, based on publicly available information

Haowen Xu

Department of Neuro-interventional Radiology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2024 in Optics Express
Verified
Journal Article
Open access
HXHao Xu
Hao Xu
SCShiqi Chen
Shiqi Chen
HHHaiquan Hu
Haiquan Hu
PLPeng Luo
Peng Luo
ZJzheyan jin
zheyan jin
TJTingting Jiang
Tingting Jiang
Hyperspectral imaging is a critical tool for gathering spatial-spectral information in various scientific research fields. As a result of improvements in spectral reconstruction algorithms, significant progress has been made in reconstructing hyperspectral images from commonly acquired RGB images. However, due to the limited input, reconstructing spectral information from RGB images is ill-posed. Furthermore, conventional camera color filter arrays (CFA) are designed for human perception and are not optimal for spectral reconstruction. To increase the diversity of wavelength encoding, we propose to place broadband encoding filters in front of the RGB camera. In this condition, the spectral sensitivity of the imaging system is determined by the filters and the camera itself. To achieve an optimal encoding scheme, we use an end-to-end optimization framework to automatically design the filters’ transmittance functions and optimize the weights of the spectral reconstruction network. Simulation experiments show that our proposed spectral reconstruction network has excellent spectral mapping capabilities. Additionally, our novel joint wavelength encoding imaging framework is superior to traditional RGB imaging systems. We develop the deeply learned filter and conduct actual shooting experiments. The spectral reconstruction results have an attractive spatial resolution and spectral accuracy.

16 August 2025 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
CHChongyang Huang
Chongyang Huang
YLYanru Liu
Yanru Liu
JZJiangang Zhang
Jiangang Zhang
SGSheng Guan
Sheng Guan
TQTao Quan
Tao Quan
HXHaowen Xu
Haowen Xu
Objective: The results of the TRACE‐III trial demonstrated that tenecteplase (TNK) might be comparable to TNK combined with mechanical thrombectomy (MT) for large vessel occlusion (LVO) stroke within 4.5 to 24 h of onset, as tested in the TIMELESS trial. We aimed to evaluate the safety and effectiveness of MT alone in TRACE‐III‐eligible patients in routine clinical settings, comparing the results of both trials.Methods: This retrospective multicenter cohort study involved consecutive patients who underwent MT alone at three stroke centers between March 2021 and July 2024. Only those meeting the inclusion and exclusion criteria of TRACE‐III were included. Safety, clinical, and imaging outcomes were compared with the TRACE‐III and TIMELESS trial data.Results: 336 TRACE‐III‐eligible patients were enrolled in our cohort. MT alone had a higher percentage of patients with a modified Rankin scale (mRS) score of 0–2 at 90 days (58.9%) compared to the TNK group in TRACE‐III, TNK and placebo groups in TIMELESS (43.6%, 46.0%, and 42.4%, respectively; all p < 0.01). Additionally, MT achieved a higher rate of early‐stage reperfusion (86.0%) compared to the TRACE‐III TNK, TIMELESS TNK, and TIMELESS placebo groups (27.9%, 76.7%, and 63.9%; all p < 0.05). The mRS 0–1 at 90 days, incidence of symptomatic intracerebral hemorrhage, and mortality at 90 days were 36.0%, 5.4%, and 14.9%, respectively, similar to those in the three groups (all p > 0.05).Interpretation: In clinical practice, MT can achieve higher rate of early‐stage reperfusion and tended to yield better functional outcomes than intravenous TNK, with similar safety, in TRACE‐III‐eligible patients.

10 June 2026 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
XXXiaoyi Xue
Xiaoyi Xue
RLRunjianya Ling
Runjianya Ling
YTYajie Tang
Yajie Tang
THTianhao Hu
Tianhao Hu
GHGuangchen He
Guangchen He
YZYueqi Zhu
Yueqi Zhu
Background: Intracranial atherosclerotic stenosis (ICAS) causes ischemia, predominantly from downstream hemodynamic compromise or perforator artery occlusion. We compared plaque morphology and composition between these mechanisms using high resolution vessel wall imaging (HR-VWI) and optical coherence tomography (OCT). Methods: We enrolled 39 patients with symptomatic ICAS presenting with cerebral infarction or transient ischemic attack (TIA). All patients underwent HR-VWI and OCT. Based on diffusion weighted imaging (DWI) and CT perfusion (CTP), patients were classified as: (1) hypoperfusion type—watershed infarction on DWI or TIA with distal hypoperfusion on CTP; or (2) perforator type—an infarct confined to a single perforator territory on DWI. Plaque features were compared between groups, and multivariable logistic regression identified imaging markers independently associated with perforator-type events. Results: On HR-VWI, perforator-type plaques more often exhibited intraplaque hemorrhage (IPH; 52.9% vs 13.6%; P=0.008), plaque ulceration (47.1% vs 13.6%; P=0.033), and a higher eccentric index (0.63±0.13 vs 0.48 (IQR 0.34); P=0.028) than hypoperfusion-type plaques. On OCT, perforator-type lesions had thinner fibrous caps (60 µm (IQR 50–80) vs 90±30 µm; P=0.004) and more frequent superficial thrombus (35.3% vs 4.5%; P=0.030) and cholesterol crystals (52.9% vs 18.2%; P=0.022). In multivariable analysis, thinner caps (per 10 µm increase, OR 0.663, 95% CI 0.481 to 0.914, P=0.012) and IPH (OR 9.703, 95% CI 1.508 to 62.429, P=0.017) were independently associated with perforator-type stroke. Conclusions: Plaques causing perforator artery occlusion showed a vulnerable phenotype characterized by a thin fibrous cap and IPH on multimodal imaging, distinguishing them from plaques underlying hemodynamic ischemia. These features may support mechanism specific risk stratification in ICAS.

9 September 2025 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
YJYazhou Jin
Yazhou Jin
YZYueqi Zhu
Yueqi Zhu
XGxinbin guo
xinbin guo
FFFeng Fan
Feng Fan
TQTao Quan
Tao Quan
HXHaowen Xu
Haowen Xu
Background: The outcomes of self-expanding stenting for symptomatic middle cerebral artery (MCA) M2 segment stenosis remain unclear. We aimed to analyze whether the safety and efficacy of M2 and M1 segment stenting procedures differ. Methods: This multicenter retrospective cohort study analyzed data from three stroke centers involving patients who underwent self-expanding stent placement for symptomatic M1 or M2 stenosis between January 2017 and August 2024. Patients were stratified into two groups: M1 stenting (M1S) and M2 stenting (M2S). Safety outcomes included 30-day peri-procedural complications, while efficacy outcomes comprised ipsilateral stroke beyond 30 days through 6 months and in-stent restenosis (ISR) at 6 months. Propensity score matching (PSM) was used to balance baseline characteristics between groups. Results: A total of 318 patients were enrolled. Compared with the M1S group, the M2S group had a similar incidence of 30-day periprocedural complications (5.0% vs 5.4%; odds ratio (OR) 1.08, 95% confidence interval (CI) 0.24 to 4.93; P=0.917), incidence of ipsilateral stroke between 30 days and 6 months postprocedure (3.1% vs 3.9%; OR 1.27, 95% CI 0.16 to 10.40; P=0.821) and ISR rate (25.0% vs 15.8%; OR 0.56, 95% CI 0.23 to 1.35; P=0.193). After a 2:1 PSM (78 vs 39 patients), the two groups remained comparable in terms of 30-day complications, the incidence of ipsilateral stroke beyond 30 days through 6 months, and the ISR rate. Conclusion: Self-expanding stenting for symptomatic M2 stenosis is technically feasible, with a safety and efficacy profile comparable to those of M1 interventions. These preliminary findings warrant validation in randomized trials.